Pain management drug developer SiteOne Therapeutics has secured Amgen as a research and development partner and lead investor in its series B round.
SiteOne Therapeutics, the US-based developer of a non-opioid pain management drug, has raised $15m in a series B round led by pharmaceutical firm Amgen as part of a research and development agreement.
Next Frontier Capital, 2M Companies, Mission Bay Capital, Sears Capital Management, Biobrit, and Z Investments participated alongside Amgen in the round.
SiteOne is developing treatments for acute or chronic pain that will work by inhibiting the Naᵥ1.7 sodium ion channel. Amgen will combine SiteOne’s drug discovery team and…
